VISION-DMD

Designed to ensure a timely & cost-effective drug development for Duchenne muscular dystrophy

Search

  • The Project
    • Summary
    • Project Objectives
    • Project Consortium
    • Contact us
  • About DMD
    • What is DMD?
    • Living with Duchenne
    • Current treatment options
    • Duchenne boy’s stories
    • DMD Community
    • Standards of Care for Duchenne muscular dystrophy
  • Study Information
    • What is a clinical study?
    • Phase 2a clinical trial information
    • Phase 2a preliminary study results
    • Phase 2b clinical trial information
    • Phase 2b Preliminary Results
    • MRI – Magnetic Resonance Imaging
  • Drug Development
    • Development of Vamorolone
    • Vamorolone development programme
  • Innovations
    • Return of patient data
    • Bone Health Outcomes
    • Biomarkers
    • Vamorolone study APP for boys
    • Patient Group Funders
    • What is Venture Philanthropy?
  • Resources
    • Relevant publications
      • VISION-DMD INFORMATION APP OVERVIEW
      • VISION-DMD Thought paper
    • VISION-DMD Workshops
      • Workshop series: Standards of Care
      • Workshop series: Biomarkers and Imaging
    • Webinars and presentations
    • Press Releases
    • VISION-DMD project Interviews
      • Collaborating for progress on rare diseases: an interview with Dr. Daria Julkowska, Scientific Coordinator of the European Joint Program on Rare Diseases.
      • Returning vamorolone study data to patient caregivers. What, when and how clinical trial data is returned to study participants. An interview with Dr. Laurie Conklin
      • An Interview with Andrea D’Alessandro – Clinical research project manager at TRiNDS
      • Interview with Jana Haberlová – Paediatric Neurologist at University Hospital Motol
      • Interview with Alex Johnson: a parent and patient foundation funder
    • VISION-DMD Project Newsletters
      • VISION-DMD newsletter sign up
    • VISION-DMD Poster presentations
    • Our privacy policy
  • English
    • Nederlands
    • Français
    • Deutsch
    • Italiano
    • Español

Press Releases

1 June 2021: Santhera and ReveraGen Announce Positive and Statistically Highly Significant Topline Results with Vamorolone in Pivotal VISION-DMD Study

10 March 2021: VISION-DMD Releases White Paper on returning individual clinical trial data to participants

3 March 2021: Santhera and ReveraGen BioPharma Announces Completion of First 6-Month Period of Pivotal VISION-DMD Trial with Vamorolone in Duchenne Muscular Dystrophy

17 November 2020: ReveraGen BioPharma receives $3.3 Million NIH grant for NDA preparations for Vamorolone

02 June 2020: ReveraGen BioPharma completes 2.5 years vamorolone treatment of 41 Duchenne muscular dystrophy boys.

17 October 2019: Vamorolone Designated Promising Innovative Medicine (PIM) for treatment in Duchenne muscular dystrophy

11 October 2019: VISION-DMD announces all UK clinical trial sites now open for recruitment for Phase 2b vamolorone study in Patients with Duchenne Muscular Dystrophy

5 October 2019: Top-line data of 18-month vamorolone treatment of Duchenne muscular dystrophy patients shows continued improvement of symptoms with reduction in corticosteroid safety concerns

August 2019: Vamorolone treatment of Duchenne Muscular Dytrophy patients leads to improvement in motor function

August 2018: First Patient Enrolment in International Pivotal Trial of Vamorolone in Duchenne Muscular Dystrophy

June 2018: Vamorolone Phase 2 top line press release

February 2018: ReveraGen BioPharma initiates VISION-DMD Phase 2b Study for Treatment of Duchenne Muscular Dystrophy

March 2017 : Vision-DMD update: ReveraGen BioPharma Receives FDA Fast Track Designation for Vamorolone for the Treatment of Duchenne Muscular Dystrophy

September 2016 :  ReveraGen BioPharma Inc initiates VISION-DMD Phase 2a Study for Treatment of Duchenne Muscular Dystrophy

Follow us on twitter

  • Twitter

EUFlag2020

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement number 667078.

To find out more about the project contact us at vision-dmd_team@ceratium.eu

VISION-DMD Copyright © 2023 · Log in

Multilingual WordPress with WPML